Clinical Trial Update: A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification [Phase 2]

View source ↗

Summary

This Phase 2 trial assessed the efficacy and safety of SAR125844 in non-small cell lung cancer patients with MET amplification and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SAR125844 (SAR125844)

Snippet

Sponsor: Sanofi | Conditions: Neoplasm Malignant | Phase 2 | Status: COMPLETED